Williams AO/AC Signals W24 2026 — 45 Signals Across 12 Sectors

Edition 8 · 2026-06-12

W23 Scorecard

🔴 MODEL OUTPUT — Published candidates from last week. No edits. No omissions.

Performance of all Category A candidates named in W23. Prices measured from the Thursday close of W23 (2026-06-10) to the Thursday close of W24 (2026-06-12). Alpha Vantage weekly bars — last bar of the trading week.

Result key: ✓ escalation · ✗ signal lost · — holding/no position. Entry Reference = Thursday close of W23 (2026-06-10). W24 Close = Thursday 2026-06-12. Source: radar.db weekly_bars.

Scorecard summary: 8 escalated · 8 lost signal · 18 holding · 24 of 34 positive · Avg Δ: +1.5% · SPY: —

Portfolio Tracker

🟢 LIVE POSITIONS — Actual entries with real or paper capital. Updated every week.

Mode: Paper

The Number of the Week

🔴 MODEL OUTPUT

45 active signals across 388 tickers analyzed — 11.6% of the universe.

Signal density reached its highest level since we began tracking the full 388-ticker universe. Last week we had 34. This week: 45. The jump is not noise — it reflects a genuine broadening of the compression. Eight names escalated from S1 to S2D, including four in healthcare alone (ABT, MDT, SYK, COO). That kind of sectoral clustering in a single escalation wave is significant.

The pre-radar also contracted sharply: from 31 names at ≤p15 last week to 23 this week. That is not because the pressure eased — it's because those names graduated into active signals. The pipeline is converting. If this pace continues into W25, we could see signal density cross 15% of the universe for the first time.

The XLV story dominates W24. Five of the eight S2D signals are in healthcare. That is a sector-specific compression event, not a broad market phenomenon. The patience discipline remains unchanged: no entry until S2 Pure confirmation. But the setup is building in healthcare in a way that deserves close attention heading into W25.

Follow-Up — W23 Key Names

🔴 MODEL OUTPUT

W24 Candidates — Category A

🔴 MODEL OUTPUT — Algorithm-generated. Not editorial picks.

The 45 tickers the model flagged as priority for W25 monitoring. Ordered by price percentile (lower = more depressed relative to 52-week range).

Decision week: W25.

S2 Signals — Week 24

🔴 MODEL OUTPUT

Pure S2 — Full Confirmation

None this week.

S2 Degraded — 8 Tickers

Pre-Radar — Approaching the Signal

🔴 MODEL OUTPUT

23 tickers at structural lows (≤p15) with no active signal yet. Names to watch heading into W25.

The Universe

388 tickers · 13 sectors Sectors covered: XLU, XLI, XLP, XLE, XLF, XLV, XLB, XLY, XLK, XLC, XLRE, IBB, XBI Market reference: SPY

Active signals by type:

• S1 active: 37
• S2 degraded: 8
• S2 pure: 0
• Tickers at structural lows (≤p15): 36

The Ticker of the Week — Deep Dive

🟡 ANALYST COMMENTARY — Editorial interpretation. Not model output.

ABT · Abbott Laboratories (XLV · p8%)

Why ABT this week: Abbott escalated to S2D at p8% after a -3.2% week — the lowest-percentile S2D escalation in a week where healthcare dominated the signal board. The setup has been building since W22. Three weeks of S1. Now the AC has crossed.

The Business. Abbott is one of the most diversified large-cap healthcare companies on the market. Revenue is split across four segments: Medical Devices (roughly 40% of sales, anchored by the Libre continuous glucose monitor franchise), Diagnostics (legacy COVID testing business now normalized), Established Pharmaceuticals (branded generics in emerging markets), and Nutrition (Similac, Ensure, PediaSure). The CGM business alone — FreeStyle Libre — has compounded at a mid-teens growth rate for five consecutive years and now serves over 6 million users globally. This is not a distressed company. It is a structurally strong business trading at a depressed level.

Why depressed. Abbott's stock spent most of 2025 under pressure from two converging headwinds. First, the post-COVID diagnostic cliff: the company had benefited from several quarters of elevated COVID testing revenue that evaporated as demand normalized. Investors took time to look through that to the underlying business, and the stock drifted accordingly. Second, litigation overhang around NEC (necrotizing enterocolitis) claims related to preterm infant formula. The legal situation is complex and unresolved; trial outcomes have been mixed; the exposure is uncertain. That uncertainty alone is enough to keep institutional buyers cautious.

The Setup. AO has been negative since W22 — the longer-term oscillator confirming sustained momentum pressure. This week AC crossed to confirm the second oscillator: a full S2D. At p8% of its 52-week range, Abbott is trading near a year of lows. The stock closed at $88.18 on Thursday. Its 52-week high is above $130. The implied mean-reversion target from the high end of the range is substantial, but that's not the trade — the trade is the oscillator re-cross, which hasn't happened yet.

Risk factors. The litigation risk is real and not fully quantifiable. If a landmark NEC verdict goes significantly against Abbott, the stock could re-rate lower regardless of fundamentals. Additionally, healthcare in general is facing uncertainty around U.S. drug pricing policy and potential Medicare/Medicaid reimbursement changes that could compress medtech margins in the medium term. Neither risk is existential for Abbott's diversified model, but both create genuine valuation uncertainty that the model cannot capture.

The patient investor case. Abbott at p8% with both oscillators confirming downward momentum is precisely the setup this system was built to identify: a high-quality business, structurally sound, temporarily dislocated by sentiment and legal noise. The strategy is to wait for S2 Pure — both oscillators crossing back above zero simultaneously — before considering any entry. When that confirmation comes, the setup will have resolved. The time to watch is W25 and W26. Until then, ABT is the top name on the watchlist.

Manager Note — W24

🟡 ANALYST COMMENTARY — Portfolio manager's macro read. Not model output.

W24 delivered the best scorecard result since we started tracking: 24 of 34 W23 candidates closed positive, with an average Δ of +1.5%. Eight names escalated to S2D — that is the highest escalation count in a single week. If you read last week's note, this is exactly the pipeline conversion I expected: the pre-radar at 31 names was a staging area, and a meaningful portion of it graduated.

The eight-name drop in pre-radar (from 31 to 23) is the story beneath the signal count. Those names didn't disappear — they moved into active signals. The compression wave that was building in XLP and XLC for several weeks has now partially converted in XLV. Healthcare generated five of the eight S2D escalations: ABT, MDT, SYK, COO, and CLX (XLP). That is a tight, sector-specific cluster that cannot be explained by broad market behavior alone. Something specific is happening in healthcare — a combination of post-COVID normalization, valuation compression relative to the market's tech concentration, and the legal overhangs mentioned in the deep dive.

The three signals lost to the ranging filter (EMR, UPS, HSY) are a useful signal in themselves. The ranging filter triggers when price action lateralizes — momentum dissipates without a directional resolution. These aren't failures; they're the system correctly identifying that the setup has expired before reaching the entry condition. Better to exit cleanly than to hold a stale signal.

The market broadly was constructive in W24, with several of our holdings printing strong weeks (CHTR +10.4%, APH +10.8%, HD +5.7%). Yet these names, despite strong weekly moves, remain at structural lows — CHTR at p5%. The combination of strong short-term moves and persistent structural positioning tells us the recovery, where it exists, is uneven. Patience remains the correct posture. No open positions. The paper portfolio continues to observe.

Published: Friday, June 12, 2026